Valneva's 15-min chart triggers KDJ Golden Cross, Bullish Marubozu Formation

Valneva's 15-minute chart recently exhibited a KDJ Golden Cross and Bullish Marubozu at 08/26/2025 11:45, indicating a shift in the momentum of the stock price towards the upside and a potential increase in value. The control of buyers in the market suggests that bullish momentum is likely to continue.

Valneva SE's stock price recently experienced a significant shift in momentum, with the 15-minute chart displaying a KDJ Golden Cross and a Bullish Marubozu at 08/26/2025 11:45. These technical indicators suggest a potential increase in the stock's value and a continuation of bullish momentum.

The KDJ Golden Cross, a bullish indicator, signals a shift in the stock's momentum from bearish to bullish. This combination of signals, along with the Bullish Marubozu, indicates that the stock price has dropped precipitously but is currently supported by fundamental factors and has the potential to rebound and continue to rise as momentum shifts in favor of the upside [1].

Analysts have expressed mixed opinions on Valneva following the FDA's suspension of the license for its Chikungunya vaccine, Ixchiq. Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 while keeping a 'Buy' rating on the shares. Despite the FDA's decision, Valneva has not revised its revenue guidance for 2025 [2].

Meanwhile, H.C. Wainwright analyst Brandon Folkes reiterated a 'Buy' rating on Valneva. The stock selloff on Monday offers an attractive entry for investors who are constructive on a potential positive readout for VLA15, the company’s investigational Lyme disease vaccine, later this year [2].

Valneva's stock has more than doubled this year, driven by demand for its chikungunya vaccine and a partnership with Pfizer on a Lyme disease shot. Analysts project a further 62% upside, with seven of eight analysts tracked by Bloomberg rating the stock a buy or equivalent [3].

Despite the recent downturn, Valneva has made notable progress in its vaccine portfolio. The company's IXCHIQ® chikungunya vaccine has achieved significant sales growth in H1 2025, driven by a €20.8M net loss and a 77.7% reduction in cash burn [1]. The vaccine's approval in Brazil, the first in an endemic country, has expanded market access and is supported by partnerships with Instituto Butantan and Serum Institute of India [1].

Valneva's pipeline diversification with Lyme disease (VLA15) in Phase 3 and Shigella/Zika candidates, along with €161.3M in cash reserves, positions the company to hedge risks and target high-growth markets. The company is also in talks with governments to combat outbreaks in the Indian Ocean and China, driven by demand for its chikungunya vaccine [1].

For long-term investors, Valneva's strengths—strong cash reserves, a diversified pipeline, and strategic access to endemic markets—outweigh the near-term risks. However, caution is warranted. The FDA's evolving stance under new leadership and the potential for further SAE reports could delay approvals or dampen uptake. Investors should monitor the Phase 3 Lyme data and the outcomes of the post-marketing IXCHIQ® study [1].

References:
[1] https://www.ainvest.com/news/valneva-15-minute-chart-shows-rsi-oversold-kdj-golden-cross-2508/
[2] https://www.ainvest.com/news/valneva-se-shares-rally-chikungunya-vaccine-clearance-lyme-disease-vaccine-trials-2508/
[3] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311